The clinical investigator

, Volume 71, Supplement 8, pp S140–S144 | Cite as

Isolated diastolic dysfunction of the myocardium and its response to CoQ10 treatment

  • P. H. Langsjoen
  • K. Folkers
Conference on Coenzyme Q


Symptoms of fatigue and activity impairment, atypical precordial pain, and cardiac arrhythmia frequently precede by years the development of congestive heart failure. Of 115 patients with these symptoms, 60 were diagnosed as having hypertensive cardiovascular disease, 27 mitral valve prolapse syndrome, and 28 chronic fatigue syndrome. These symptoms are common with diastolic dysfunction, and diastolic function is energy dependent. All patients had blood pressure, clinical status, coenzyme Q10 (CoQ10) blood levels and echocardiographic measurement of diastolic function, systolic function, and myocardial thickness recorded before and after CoQ10 replacement. At control, 63 patients were functional class III and 54 class II; all showed diastolic dysfunction; the mean CoQ10 blood level was 0.855 μNg/ml; 65%,15%, and 7% showed significant myocardial hypertrophy, and 87%, 30%, and 11% had elevated blood pressure readings in hypertensive disease, mitral valve prolapse and chronic fatigue syndrome respectively. Except for higher blood pressure levels and more myocardial thickening in the hypertensive patients, there was little difference between the three groups. CoQ10 administration resulted in improvement in all; reduction in high blood pressure in 80%, and improvement in diastolic function in all patients with follow-up echocardiograms to date; a reduction in myocardial thickness in 53% of hypertensives and 36% of the combined prolapse and fatigue syndrome groups; and a reduced fractional shortening in those high at control and an increase in those initially low. Isolated diastolic dysfunction associated with moderately low CoQ10 blood levels is an extremely frequent finding in patients with three varied clinical entities sharing similar symptoms and CoQ10 replacement results in clinical improvement, lowering of elevated blood pressures, improved diastolic function, a decrease in myocardial thickness, and a normalization of systolic function.

Key words

Diastolic dysfunction Coenzyme Q10 Hypertension Mitral valve prolapse Fatigue 



Coenzyme Q10


Hypertensive cardiovascular disease


Mitral valve prolapse syndrome


Chronic fatigue syndrome


  1. 1.
    Langsjoen PH, Langsjoen PH, Folkers K (1990) Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 65:521–523Google Scholar
  2. 2.
    Weber KT, Anversa P, Armstrong PW et al (1992) Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 20:3–16Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • P. H. Langsjoen
    • 1
  • K. Folkers
    • 1
  1. 1.TylerUSA

Personalised recommendations